Press Releases 2016-11-18T12:35:28+00:00

Press Releases

9Dec, 2016

Alzheon Presents Analyses from Phase 3 Clinical Studies Showing Largest Clinical Effects of Tramiprosate, the Active Molecule of ALZ-801, in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease

December 9th, 2016|Categories: Press Release|

Results Support ‘Precision Medicine’ Approach in Alzheimer’s Drug Development and Pivotal Study of ALZ-801 in Genetically-Defined Patients with Mild Alzheimer’s Disease to Begin in 2017 Clinical [...]

21Nov, 2016

Alzheon to Present New Clinical Data and Analyses for ALZ-801, an Amyloid-Targeted Drug Candidate, and its Active Molecule Tramiprosate at the 9th Clinical Trials on Alzheimer’s Disease Congress

November 21st, 2016|Categories: Press Release|

FRAMINGHAM, Mass., November 21, 2016 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological [...]

Load More